XIIDRA

This brand name is authorized in United States. It is also authorized in Canada.

Active ingredients

The drug XIIDRA contains one active pharmaceutical ingredient (API):

1	Lifitegrast UNII 038E5L962W - LIFITEGRAST
	Lifitegrast is a lymphocyte function-associated antigen-1 (LFA-1) antagonist. It binds to the integrin LFA-1, a cell surface protein found on leukocytes and blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED.
	Read more about Lifitegrast

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
XIIDRA Οphthalmic solution	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01XA25		S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA25

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02471027
US	FDA, National Drug Code	0078-0911, 54092-606